When we soon hear of the updated deal with Zeiss it will be interesting to compare it to the original deal.
Here's the press release from that time.
3 July 2007
Optiscan and Carl Zeiss Group sign collaboration deal
• Optiscan’s first rigid endo-microscope deal
• Carl Zeiss Group secure exclusive use of Optiscan technology for clinical rigid
endo-microscope applications in their core market segments
• A$20 million of milestone payments and product sales anticipated over the
initial 5 years
• Carl Zeiss Group to fund market development and sales of “ZEISS” branded
instruments produced by Optiscan
• Optiscan retains rights to separately commercialise other segments of rigid
endo-microscope market
MELBOURNE, Australia: Carl Zeiss Group and Optiscan Imaging Limited today
executed an exclusive, milestone based cooperation agreement to develop, market and
sell confocal endo-microscopes.
The medical instruments to be cooperatively developed under this agreement will be
exclusively marketed and sold by Carl Zeiss through their global sales force under the
famous ZEISS brand name.
Matthew Barnett, Optiscan’s CEO said, “Carl Zeiss is world renowned for the quality of
their optical instruments. Optiscan is very pleased to have Carl Zeiss as our first
commercial partner in rigid endo-microscopes. Carl Zeiss’ global market leadership and
strong track record of innovation makes them the ideal partner for Optiscan.”
Optiscan and Carl Zeiss Cooperation Agreement Details
• Total value of agreement to Optiscan in milestone payments and expected product
sales is A$20 million over the initial five years.
• Utilising its patented endo-microscope platform, Optiscan will work with Carl Zeiss
to develop an endo-microscope instrument specifically designed for use by clinical
specialists in key ZEISS markets.
• Carl Zeiss will be responsible for costs associated with endo-microscope
integration into their existing product platform, as well as market development,
marketing and instrument sales.
• The agreement includes milestone-based payments to Optiscan of A$4 million for
successfully completing development activities required to market. Milestone payments
are expected over the first 3 years.
Specific details of milestones and payments are commercial in confidence.
• Optiscan will manufacture the endo-microscopes in its recently upgraded, state of
the art Australian manufacturing facility. The instruments will be exported to Carl
Zeiss in Germany prior to shipping to global customers
Add to My Watchlist
What is My Watchlist?
